Secura Bio Reports Completion of Enrollment in P-II (PRIMO) Study of Copiktra (duvelisib) for the Treatment of Peripheral T-cell Lymphoma
Shots:
- The company has completed enrollment in P-II (PRIMO) dose optimization & expansion study to evaluate Copiktra in 157 patients with r/r PTCL
- The 1EPs of the expansion study are ORR & 2EPs include additional efficacy measures including DoR, PFS, PK & safety. In an interim analysis of 78 patients in the expansion phase with a minimum follow-up of 6mos., ORR (50%); CR rate (32.1%); m-DoR of 233 days, 80% remain on therapy; 47.4% & 19.2% discontinued due to PD & unacceptable toxicity, 6.4% discontinued for stem cell transplant
- Copiktra is a PI3K inhibitor & 1st US approved dual inhibitor of PI3K-delta & PI3K-gamma. The therapy has received FTD for PTCL & ODD for T-cell lymphomas
Ref: PR Newswire | Image: LinkedIn
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com